A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular disease

Trial Profile

A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Macitentan (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms SERENADE
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 14 Aug 2017 Last checked against ClinicalTrials.gov record.
    • 10 Aug 2017 Planned End Date changed from 10 Mar 2020 to 14 Mar 2020.
    • 10 Aug 2017 Planned primary completion date changed from 10 Mar 2020 to 14 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top